JMP Securities Reaffirms “Market Outperform” Rating for Savara (NASDAQ:SVRA)

JMP Securities reaffirmed their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $9.00 price objective on the stock.

SVRA has been the topic of a number of other reports. HC Wainwright reduced their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $9.86.

Savara Stock Performance

Shares of SVRA opened at $3.23 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The company has a market cap of $554.33 million, a price-to-earnings ratio of -7.51 and a beta of 0.92. The stock has a fifty day moving average price of $3.47 and a two-hundred day moving average price of $3.98. Savara has a 52-week low of $2.82 and a 52-week high of $5.70.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11). Analysts predict that Savara will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Savara news, CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Joseph S. Mccracken purchased 20,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 5.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Savara

Institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company raised its position in shares of Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock valued at $191,000 after acquiring an additional 3,706 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Savara by 5.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock worth $533,000 after purchasing an additional 6,141 shares during the period. Principal Financial Group Inc. raised its holdings in Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the period. ClariVest Asset Management LLC boosted its position in shares of Savara by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 256,479 shares of the company’s stock worth $1,034,000 after purchasing an additional 7,170 shares in the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Savara by 7.0% in the 3rd quarter. Victory Capital Management Inc. now owns 140,010 shares of the company’s stock valued at $594,000 after buying an additional 9,180 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.